(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 April 2009 (30.04.2009)

PCT

(10) International Publication Number
WO 2009/055721 A3

(51) **International Patent Classification**:
C07D 403/08 (2006.01) ***C07D 209/04*** (2006.01)
C07D 403/02 (2006.01)

(21) **International Application Number**:
PCT/US2008/081190

(22) **International Filing Date**:
24 October 2008 (24.10.2008)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
60/983,124 26 October 2007 (26.10.2007) US
60/983,119 26 October 2007 (26.10.2007) US

(71) **Applicant** *(for all designated States except US)*: **AMIRA PHARMACEUTICALS, INC.** [US/US]; 9535 Waples Street, Suite 100, San Diego, CA 92121 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **REWOLINSKI, Melissa, Virginia** [US/US]; 11636 Alderhill Terrace, San Diego, CA 92131 (US). **SCHAAB, Kevin, Murray** [US/US]; 4275 Orchard Drive, Spring Valley, CA 91977 (US). **KING, Christopher, David** [US/US]; 7396 Escallonia Court, Carlsbad, CA 92011 (US). **EVANS, Jillian, F.** [CA/US]; 12770 Eastridge Court, San Diego, CA 92131 (US). **PRASIT, Petpiboon, Peppi** [CA/US]; P.O. Box 3734, Rancho Santa Fe, CA 92067 (US). **HUTCHINSON, John, Howard** [US/US]; 5948 Via Zurita, La Jolla, CA 92037 (US). **STOCK, Nicholas, Simon** [GB/US]; 7087 Camino Degrazia #150, San Diego, CA 92111 (US).

(74) **Agents**: **GLAXO SMITH KLINE** et al.; 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) **Title**: 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR

Figure 8



Lack of CYP3A4 and 2C9 Induction

(57) **Abstract**: Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

WO 2009/055721 A3

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
20 August 2009